Where does Clarify Analytical rank among its competitors?

Clarify Analytical ranks 224th amongst 218 active competitors, of which 23 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AFYREN, which secured $3.51M in Apr, 2026.

Who are the top competitors of Clarify Analytical?

Clarify Analytical's top competitors include AFYREN, Phylos Bioscience and Spore Biotechnologies. Among them, AFYREN secured the most recent funding round in April, 2026.

Clarify Analytical - 2026 Company Profile & Competitors

Clarify Analytical is a funded company. It operates as a Developer of mass spectrometry-based analytical methodologies for biomarker detection and diagnostic research. The company has 218 active competitors, including 23 funded and 28 that have exited. Its top competitors include companies like AFYREN, Phylos Bioscience and Spore Biotechnologies.

Company Details

Developer of mass spectrometry-based analytical methodologies for biomarker detection and diagnostic research. It is focused on developing advanced mass spectrometry-based methodologies. Its reported work includes developing a test for detecting lupus-specific biomarkers to support disease diagnosis.

Key Metrics

Stage

Funding Raised

Ranked

224^th among 250 competitors

Similar Companies

Omass & 165 more

View Clarify Analytical's full profile

Clarify Analytical is a funded company.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Clarify Analytical include AFYREN, Phylos Bioscience and Spore Biotechnologies. Here is the list of Top 10 competitors of Clarify Analytical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AFYREN 2012, Paris (France), Public	Provider of analytical services for microbiology, chemistry and bioprocesses industries	$132M	Kemin, Sofinnova Partners & 12 others	64/100
2nd	Phylos Bioscience 2014, Portland (United States), Series B	Developer of cannabis F1 hybrid seeds and natural THC products	$31.2M	Merida Capital Partners, Entourage Effect Capital ... & 6 others	60/100
3rd	Spore Biotechnologies 2022, Paris (France), Series A	Developer of microbial detection technology for life science industries	$35M	Singular, LocalGlobe & 15 others	56/100
4th	Omass 2016, Oxford (United Kingdom), Acquired	Offers mass spectrometry related services	$19.3M	Syncona, Oxford Science Enterprises	56/100
5th	Steep Hill 2008, Berkeley (United States), Series A	Provider of cannabis testing and analytics services	$15.3M	Phyto Partners, Poseidon Asset Management ... & 4 others	53/100
6th	Agilex Biolabs 2009, Thebarton (Australia), Acquired	Provider of regulated bioanalytical services for preclinical and clinical drug development	-	Genesis Capital	48/100
7th	Clearbridge Health 2010, Singapore (Singapore), Public	Service provider of non-invasive urine, non-esoteric and esoteric testing, and tissues analysis	-	Asdew Acquisitions, Kolibra Capital & 3 others	44/100
8th	Shanghai Xihua Scientific 2015, Shanghai (China), Seed	Provider of analytical services in the clinical research of drugs	-	Gl-investment, Lilly Asia Ventures	44/100
9th	Actlabs 1987, Hamilton (Canada), Series A	Provider of analytical testing and development services for various industries. It offers services to clients ranging from academic research to routine quality control. These services support agriculture, cannabis, environmental, forensic, geochemical, geochronological, life sciences, materials testing, metallurgical, mineralogical, oil and gas exploration, and pharmaceutical sectors. The company utilizes innovative technologies and is committed to superior customer service. Its services encompass a wide spectrum of analytical needs.	$2M	-	43/100
10th	Crawford Scientific 1985, Strathaven (United Kingdom), Acquired	Service provider in analytical testing	$9.78M	Maven Capital Partners, Clydesdale Bank	43/100
224th	Clarify Analytical Funding Raised	Developer of mass spectrometry-based analytical methodologies for biomarker detection and diagnostic research	-	-	16/100